✓ Translated by DotMD AI Clinical Council Source: JAMA network open • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #37768659 ↗

Randomized Controlled Trial: Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication (N = 125)

Original Paper Title: “Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 125
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The CAN-BIND cohort included 125 participants (mean [SD] age, 36.4 [13.0] years; 78 [62.4%] women), and the EMBARC sertraline treatment group included 105 participants (mean [SD] age, 38.4 [13.8] years; 72 [68.6%] women).
  • Study Design & Sample: Randomized Controlled Trial published in JAMA network open (N = 125 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in JAMA network open (2023), this randomized controlled trial evaluating 125 human participants investigated: To establish a model based on electroencephalography (EEG) to predict response to 2 distinct selective serotonin reuptake inhibitor (SSRI) medications. Key clinical takeaway: The CAN-BIND cohort included 125 participants (mean [SD] age, 36.4 [13.0] years; 78 [62.4%] women), and the EMBARC sertraline treatment group included 105 participants (mean [SD] age, 38.4 [13.8] years; 72 [68.6%] women).

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (JAMA network open, 2023-09-05; N = 125; Rigor 88/100): The CAN-BIND cohort included 125 participants (mean [SD] age, 36.4 [13.0] years; 78 [62.4%] women), and the EMBARC sertraline treatment group included 105 participants (mean [SD] age, 38.4 [13.8] years; 72 [68.6%] women).

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: sertraline-hcl → Rx: sertraline-hydrochloride → Rx: escitalopram-oxalate → Rx: escitalopram → Condition: manic-episode-in-partial-remission → Condition: bipolar-disorder-current-episode-hypomanic →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 37768659: Randomized Controlled Trial: Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication (N = 125)

3 of 3 Free Questions Remaining